INmune Bio(US:INMB) Globenewswire·2025-04-01 11:00Core Insights - INmune Bio, Inc. is presenting data from the MINDFuL Phase II trial at the International Conference on Alzheimer's and Parkinson's Diseases, focusing on early Alzheimer's disease (AD) and inflammation biomarkers [1][5] - The trial enrolled 208 patients, with 44% diagnosed with Mild Cognitive Impairment (MCI) and 56% with mild AD, averaging 72 years of age [2] - The primary endpoint is the change in cognitive scores measured by the Early and Mild Alzheimer's Cognitive Composite (EMACC), which is designed for sensitivity in early AD trials [3] Patient Demographics and Trial Design - The enrolled patients met criteria for inflammation biomarkers, including hsCRP > 1.5 mg/L, ESR > 10 mm/hr, HbA1c > 6.0%, or at least one APOE ε4 allele [2] - Patients were randomized in a 2:1 ratio to receive XPro™ (1.0 mg/kg) or placebo weekly for 23 weeks [2] - The screen failure rate was 72%, primarily due to disease severity as measured by the MMSE [4] Preliminary Findings - Preliminary analyses indicate a well-characterized cohort with 69.2% being APOE ε4 carriers and 64.4% meeting criteria for multiple enrichment biomarkers [5] - Secondary endpoints include CDR-SB, E-Cog, ADL, and Neuropsychiatric Inventory (NPI), along with blood biomarker and neuroimaging outcomes [5] - Topline results from the MINDFuL trial are expected to be reported in June 2025 [6] Company Overview - INmune Bio is a clinical-stage biotechnology company focused on treatments targeting the innate immune system, with three product platforms including DN-TNF, NK Cell Priming, and CORDStrom™ [7] - The company is developing therapies for Mild Alzheimer's disease, Mild Cognitive Impairment, and treatment-resistant depression [7]